LCM
TRVI icon

Landscape Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Landscape Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,085
Closed -$215K – 870
2024
Q4 		$215K Sell
52,085
-372,640
-88% -$1.19M 0.02% 578
2024
Q3 		$1.42M Sell
424,725
-180,717
-30% -$537K 0.14% 206
2024
Q2 		$1.8M Sell
605,442
-134,686
-18% -$374K 0.15% 201
2024
Q1 		$2.55M Sell
740,128
-169,966
-19% -$379K 0.22% 129
2023
Q4 		$1.22M Buy
+910,094
New +$1.38M 0.11% 184

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Landscape Capital Management's TRVI Position: Q1 2025 in Review

Landscape Capital Management sold out of Trevi Therapeutics (TRVI) in Q1 2025, closing a stake of 52,085 shares — an estimated $215K sold.

Landscape Capital Management first reported a position in TRVI in Q4 2023 and held it in 5 quarters. The position peaked at $2.55M in Q1 2024. 137 funds tracked by Wall St. Rank hold TRVI as of Q1 2025.

  • Landscape Capital Management reported no remaining Trevi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Landscape Capital Management sold 52,085 Trevi Therapeutics shares in Q1 2025, an estimated $215K.
  • Landscape Capital Management first reported a position in Trevi Therapeutics in Q4 2023 and held it in 5 quarters.
  • Landscape Capital Management's Trevi Therapeutics position peaked at $2.55M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2025.

Based on Landscape Capital Management's 13F filing for Q1 2025, filed 14 May 2025.